|
|
|
|
|
An exciting collaborative funding opportunity for
SMEs involved in paediatric formulations to work with large pharma. |
The Academy of Pharmaceutical
Sciences (APS) is hosting a workshop to identify SMEs to work
alongside Pharma members of the Industrial Leadership Group of the
Formulation Special Interest Group (SIG) (including large pharma) to apply for funding to address the challenges of
taste masking for paediatric formulations. SMEs with technologies
applicable to this area are invited to contribute to the proposal
and, if possible, attend a workshop at the DeVere Orchard Hotel, East
Midlands Conference Centre, University of Nottingham on Wednesday
22nd May 10am-4pm. This is a great opportunity to attract funding
for your business to support and increase research, development and
engagement with large pharma and academia.
The aim of the workshop is to
develop radical generic answers for pharma in this area hence all
potential collaborators with experience in this area (pharma or other)
are invited to attend. The session will develop a strategy to deliver
resolutions in this area and will be used to engage with relevant
funding bodies for support. Please register by Tuesday 21st May 2013 at
the e-mail below. Due to the short notice of this meeting, if you are
interested in this area and would be willing to contribute but cannot
attend please register your details and interests by e-mailing
[email protected].
Teleconference facilities will be available at this meeting should you
wish to dial in.
Problem Statement:
Lack of a generic platform for taste-masking of pharmaceutical
compounds: The pharmaceutical industry is obliged to provide a suitable
paediatric formulation for all new products at time of filing. To date
there is no generic technology and limited progress in the areas of
modelling, suitable analytical tools in the area or palatability or
biopharm understanding and in-vivo/in-vitro correlation to assess
potential formulation solutions. The aim of this work will provide
opportunities to deliver a palatable dose to the patient without
impeding its release profile. |
|
|
|
|
|